HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Sept. 25, 2015 (HealthDay News) -- Recommendations have been developed for the management of adult patients with supraventricular tachycardia (SVT). The guideline was published online Sept. 23 in the Journal of the American College of Cardiology.
Richard L. Page, M.D., from the University of Wisconsin School of Medicine in Madison, and colleagues conducted an extensive evidence review to develop recommendations on management of adults with all types of SVT other than atrial fibrillation.
The researchers note that the prevalence of SVT is about 2.25 per 1,000 persons in the general population. SVT is often diagnosed in the emergency department. Modes of presentation include documented SVT, palpitations, chest pain, syncope, atrial fibrillation, and sudden cardiac death; the need to differentiate symptoms of SVT from those of panic and anxiety disorders is a confounding factor in diagnosis.
"The overall goal of the guideline is to provide clinicians with the tools needed to successfully diagnose and treat patients with supraventricular tachycardia upon presentation in the inpatient or outpatient setting," Page said in a statement.
Several members of the writing committee and reviewers disclosed financial ties to the pharmaceutical and medical device industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022